Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment.

Haixia SunYinhui LiuYufeng ZhangYusheng JieYuankai WuZhanyi LiXuxia Wei Xiangyong Li

Published in: BioMed research international (2022)

Discontinuation of NUCs may be acceptable in patients whose HBsAg levels fall to <0.05 IU/mL. Consolidation therapy lasting <1 year appears adequate to prevent poor long-term prognosis.

Keyphrases

hepatitis b virus
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
patient reported outcomes
mesenchymal stem cells
cell therapy
smoking cessation